VJHemOnc Podcast

Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies

Myeloid Monthly: breaking news & updates from the classification advancement meeting

How AI is transforming hematologic oncology

MRD in ALL and AML: from prognostic marker to clinical endpoint

Nursing in CAR-T & cellular therapy: updates and insights from the EBMT-EHA CAR T-cell Meeting 2026

Recent BTK inhibitor trial updates across non-Hodgkin lymphoma subtypes

ASH 2025 highlights in AL amyloidosis: risk stratification, bispecific antibodies, CAR-T, & MRD

Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, venetoclax-based triplets, & emerging immunotherapies

Managing and preventing differentiation syndrome in APL

Top ASH 2025 NHL updates: novel CAR T-cell therapies, fixed-duration strategies, evolving frontline approaches, & more

Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T, trispecific antibodies, and more!

Top CLL updates from ASH 2025: novel BTKi monotherapy and combination approaches, BTK degraders, & more

Top updates in MDS from ASH 2025: key trial updates and debated topics

Sickle cell disease management: navigating the transition from pediatric to adult care, managing VOCs, & more

Accelerated- and blast-phase MPNs: diagnosis, management, and current challenges

The value and utility of MRD in the management of adults with newly-diagnosed AML

Updates from iwHRMM: targeted and immune-related therapies and mechanisms of resistance

Advances in immunotherapy for NHL: updates from iwNHL 2025

Reviewing recent guideline updates on the risk stratification and treatment of AML

The management of CLL in resource-limited settings: guideline development and ongoing projects

The multi-disciplinary team in CAR-T therapy: insights from a nurse, a neurologist, and a palliative care specialist

Understanding financial and time toxicity in cancer care: advice for community oncologists

Listener Q&A special: expert insights on CLL, myeloma, and lymphoma

Novel strategies and advances in the management and classification of MDS: insights from iwMDS 2025

Advances in Waldenström’s macroglobulinemia: significance of genetic alterations, current treatment strategies, & ongoing trials

FLT3-ITD+ AML: recent trial updates, novel approaches, and MRD

Extramedullary disease in multiple myeloma: biology, management strategies, & the RedirecTT-1 trial

iwMPN 2025 highlights: novel approaches to the upfront management of myelofibrosis, cardiovascular health in MPNs, & more

Managing CNS lymphoma: expert insights and updates from ICML 2025

iwMDS wrap-up: translating research into practice to optimize patient care

Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification

Treating elderly or unfit patients with AML: current approach and future directions

Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!

CHIP & CCUS: advances in understanding and should we treat these precursor conditions?

Diagnosing amyloidosis: identifying early signs, appropriate diagnostic tests, and challenges that remain

IPIG 2025 Highlights: challenging situations in PNH, updates from the COMMODORE trials, and more

Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease

Gene therapy in sickle cell disease: patient selection, potential complications, & more

Highlights from iwCAR-T 2025: improving the efficacy and safety of CAR T-cells & access in the community

Updates to the ESMO CLL clinical practice guidelines and implications for relapsed therapy

Highlights from iwMyeloma 2025: trial updates and practical considerations

Updates to the ESMO CLL clinical practice guidelines: implications for frontline treatment

Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more

Sequencing therapies in R/R NHL: immunotherapy in DLBCL, BTKis in MCL, & more!

Novel CAR strategies being explored in lymphoma: allogeneic products, trispecific CARs & new manufacturing platforms

Approaches to optimizing induction therapy in AML: FLT3 inhibitors, menin inhibitors, CPX-351, & more!

Treating R/R mantle cell lymphoma: the role of BTK inhibitors, combination approaches being explored & overcoming resistance

Addressing unmet needs in myeloma: early detection, frail/elderly patients, triple-class exposed disease, & more!

CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes

Post-ASH amyloidosis highlights: the ANDROMEDA trial, risk stratification, value of MRD, & more!